Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: Samsung Bioepis’ Ustekinumab Biosimilar Approved in US

Jul 1, 2024

On 1 July 2024, Samsung Bioepis announced that the FDA approved its Pyzchiva® (SB17), biosimilar to Janssen’s Stelara® (ustekinumab) for multiple indications, including moderate to severe plaque psoriasis, active psoriatic arthritis and moderately to severely active Crohn’s disease and ulcerative colitis.  The FDA has provisionally determined Pyzchiva® as interchangeable with Stelara®. 

Samsung Bioepis is licensed to launch Pyzchiva® in the US in Q2 2025, under a  settlement and licence agreement with J&J entered into in November 2023 resolving pending US litigation between the companies. 

Samsung Bioepis’ SB17 was approved in April 2024 in  Europe (as Pyzchiva®)  and  Korea (as Epyztek™).  Pyzchiva® will be commercialised by Sandoz in EEA, Switzerland, UK, US and Canada pursuant to a  deal entered into in September 2023  between Sandoz and Samsung Bioepis.

A number of ustekinumab biosimilars are currently approved in Europe, including Alvotech and STADA’s Uzpruvo® (January 2024).  Amgen’s Wezenla® received a positive CHMP recommendation in April 2024.